Short answer
Coherus Oncology, Inc. (CHRS) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Special dividend of contingent value rights declared by Coherus Oncology’s board.
Coherus Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Special dividend of contingent value rights declared by Coherus Oncology’s board
- CVR terms and shareholder FAQ available through the company’s website
- Press release and FAQ furnished as Exhibits 99.1 and 99.2
- Investors should review the CVR documents for entitlement, valuation, and payment conditions
Item 8.01 · Other Events
- One CVR per common share held at 5:00 p.m. ET on September 30, 2026
- Payments depend on net cash proceeds from Legacy BioSim Asset monetization during October 7, 2026–October 7, 2028
- Investment bank retained to support sale of patents, royalties, cell lines, and related materials
- Loan Agreement restricts Legacy BioSim Asset dispositions and CVR payments, potentially limiting timing or proceeds
- CVRs are non-transferable, unlisted, non-interest-bearing contractual rights without voting, dividend, or ownership rights
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Coherus Oncology, Inc. 8-K filings
Get the next CHRS 8-K as it lands
Follow CHRS for push alerts, or ask the research agent what this filing means.